


AMENDMENT

Kindly amend the application, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows.

In the Claims

1. (Currently amended) Compounds of Formula (I)




wherein

A is a group of the formula $-\text{C}(\text{CH}_3)=\text{CHR}^5$ or $-\text{CH}=\text{CHR}^5$, wherein R^5 is a heteroaryl- or a heteroarylalkyl group,

U is hydrogen, halogen, $\text{C}_1\text{-C}_4$ alkyl, $\text{C}_3\text{-C}_4$ -cycloalkyl, $\text{C}_1\text{-C}_4$ heteroalkyl-, trifluoromethyl or COOH,

G-E is selected from the following groups,



or is part of an optionally substituted phenyl ring,

R^1 is a $\text{C}_1\text{-C}_4$ -alkyl-, a $\text{C}_2\text{-C}_4$ -alkenyl-, a $\text{C}_2\text{-C}_4$ -alkinyl- or a $\text{C}_3\text{-C}_4$ -cycloalkyl-group,

V-W is a group of formula CH_2CH or $\text{CH}=\text{C}$,



X is oxygen or a group of the formula NR^2 , wherein R^2 is hydrogen, $\text{C}_1\text{-C}_4$ alkyl, $\text{C}_2\text{-C}_4$ alkenyl, or $\text{C}_1\text{-C}_4$ heteroalkyl,

and

R^3 and R^4 independently from each other represent hydrogen, C₁-C₄-alkyl or together are part of a cycloalkyl group with 3 or 4 ring atoms, or a pharmacologically acceptable salt, ~~solvate, hydrate~~ or formulation thereof.

2. (Cancelled)

3. (Original) Compounds according to claim 1, wherein A is a group of formula (II) or (III)



wherein Q is sulphur, oxygen or NR⁷, wherein R⁷ is hydrogen, C₁-C₄ alkyl or C₁-C₄ heteroalkyl, z is Nitrogen or CH and R⁶ is OR⁸, NHR⁸, C₁-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkinyl or C₁-C₆ heteroalkyl, wherein R⁸ is hydrogen, C₁-C₄ alkyl or C₁-C₄ heteroalkyl.


4. (Previously presented) Compounds according to claim 1, wherein X is oxygen or NH.

5. (Previously presented) Compounds according to claim 1, wherein R¹ is methyl or ethyl.

6. (Previously presented) Compounds according to claim 1, wherein R³ and R⁴ are methyl groups.

7. (Previously presented) Compounds according to claim 1, wherein U is hydrogen, fluorine, methyl, trifluoromethyl or COOH.

8. (Previously presented) Compounds according to claim 1, wherein G-E is selected from the following groups:




9. (Previously presented) Compounds according to claim 1, wherein V-W is CH₂CH.

10. (Currently amended) Pharmaceutical compositions containing a compound[[,]] or a pharmacologically acceptable salt, a solvate or a hydrate according to claim 1 or a prodrug of the compound[[,]] and/or the salt, the solvate and/or the hydrate and optionally one [[of]] or more carriers and/or one or more adjuvants and/or one or more diluents.

11. (Previously presented) Method of treating a disease selected from the group consisting of breast, ovarian, lung and prostate cancer through administering a pharmaceutically effective amount of a compound or a pharmaceutical composition according to claim 1.

12. (Cancelled)

13. (Previously presented) Compounds of formula (Va) and (Vb),



wherein the groups PG independently from each other represent hydrogen or protecting groups.

14. (Previously presented) A process for preparing a compound of formula (I), comprising reacting a compound according to claim 13 by

- a) deprotecting the acid;
- b) deprotecting the allyl alcohol;
- c) lactonizing the hydroxy acid;
- d) deprotecting the remaining alcohols;
- e) reducing the disubstituted double bond, if present; and
- f) oxidizing the sulfur atom at the 5-position to a sulfoxide.